These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17393579)

  • 1. mTOR signaling: implications for cancer and anticancer therapy.
    Petroulakis E; Mamane Y; Le Bacquer O; Shahbazian D; Sonenberg N
    Br J Cancer; 2007; 96 Suppl():R11-5. PubMed ID: 17393579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR signaling: implications for cancer and anticancer therapy.
    Petroulakis E; Mamane Y; Le Bacquer O; Shahbazian D; Sonenberg N
    Br J Cancer; 2006 Jan; 94(2):195-9. PubMed ID: 16404421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation initiation: a critical signalling node in cancer.
    Robert F; Pelletier J
    Expert Opin Ther Targets; 2009 Nov; 13(11):1279-93. PubMed ID: 19705976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J; Sassano A; Hay N; Platanias LC
    Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
    Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
    Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
    J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
    Graff JR; Konicek BW; Carter JH; Marcusson EG
    Cancer Res; 2008 Feb; 68(3):631-4. PubMed ID: 18245460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
    Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
    Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raptor-rictor axis in TGFbeta-induced protein synthesis.
    Das F; Ghosh-Choudhury N; Mahimainathan L; Venkatesan B; Feliers D; Riley DJ; Kasinath BS; Choudhury GG
    Cell Signal; 2008 Feb; 20(2):409-23. PubMed ID: 18068336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X; Jin HR; Lee D; Lee JH; Kim SK; Lee JJ
    Eur J Pharmacol; 2008 Sep; 592(1-3):41-7. PubMed ID: 18639543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R; Wang L; Fan J; Zhou Q
    Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation.
    Murooka TT; Rahbar R; Fish EN
    Biochem Biophys Res Commun; 2009 Sep; 387(2):381-6. PubMed ID: 19607806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
    Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
    J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
    Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T; Karashima H
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring mammalian target of rapamycin (mTOR) activity.
    Ikenoue T; Hong S; Inoki K
    Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.